Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’

Andrássy, K.

doi:10.1038/ki.2013.243

Cited by 965 publications

(700 citation statements)

References 6 publications

Supporting

Mentioning

632

Contrasting

Unclassified

Order By: Relevance

“…Chronic kidney disease (CKD) is defined by a reduction of the glomerular filtration rate (mostly expressed as estimated GFR or eGFR) and/or the presence of urine abnormalities, such as albuminuria, which last for longer than 3 mo (Andrassy 2013). Usually, an eGFR above 60 mL/min/ 1.73m 2 , without any other signs of renal pathology, is classified as normal renal function, while it is defined as stage I or II when albuminuria (>30 mg/d), hematuria, or other pathologies are present.…”

Section: Introductionmentioning

confidence: 99%

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Khurana

Ranches

Schafferer

et al. 2016

RNA

115

117

View full text Add to dashboard Cite

In chronic kidney disease (CKD), the decline in the glomerular filtration rate is associated with increased morbidity and mortality and thus poses a major challenge for healthcare systems. While the contribution of tissue-derived miRNAs and mRNAs to CKD progression has been extensively studied, little is known about the role of urinary exosomes and their association with CKD. Exosomes are small, membrane-derived endocytic vesicles that contribute to cell-to-cell communication and are present in various body fluids, such as blood or urine. Next-generation sequencing approaches have revealed that exosomes are enriched in noncoding RNAs and thus exhibit great potential for sensitive nucleic acid biomarkers in various human diseases. Therefore, in this study we aimed to identify urinary exosomal ncRNAs as novel biomarkers for diagnosis of CKD. Since up to now most approaches have focused on the class of miRNAs, we extended our analysis to several other noncoding RNA classes, such as tRNAs, tRNA fragments (tRFs), mitochondrial tRNAs, or lincRNAs. For their computational identification from RNA-seq data, we developed a novel computational pipeline, designated as ncRNASeqScan. By these analyses, in CKD patients we identified 30 differentially expressed ncRNAs, derived from urinary exosomes, as suitable biomarkers for early diagnosis. Thereby, miRNA-181a appeared as the most robust and stable potential biomarker, being significantly decreased by about 200-fold in exosomes of CKD patients compared to healthy controls. Using a cell culture system for CKD indicated that urinary exosomes might indeed originate from renal proximal tubular epithelial cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Khurana

Ranches

Schafferer

et al. 2016

RNA

115

117

View full text Add to dashboard Cite

show abstract

“…The results were multiplied by 1.174 as indicated in the Siemens customer bulletin to adjust to the values obtained with the assay standardized to the new traceable International Reference Preparation (IRP) - ERM®-DA471/IFCC as recommended by the KDIGO (Kidney Disease Improving Global Outcomes) [11]. The normal reference range of CysC was 0.55-1.06 mg/l.…”

Section: Methodsmentioning

confidence: 99%

Combined Serum Creatinine and Cystatin C Schwartz Formula Predicts Kidney Function Better than the Combined CKD-EPI Formula in Children

Chehade

Cachat²,

Jannot³

et al. 2013

Am J Nephrol

View full text Add to dashboard Cite

Background: The combined serum creatinine (SCreat) and cystatin C (CysC) CKD-EPI formula constitutes a new advance for glomerular filtration rate (GFR) estimation in adults. Using inulin clearances (iGFRs), the revised SCreat and the combined Schwartz formulas, this study aims to evaluate the applicability of the combined CKD-EPI formula in children. Method: 201 iGFRs for 201 children were analyzed and divided by chronic kidney disease (CKD) stages (iGFRs ≥90 ml/min/1.73 m², 90 > iGFRs > 60, and iGFRs ≤59), and by age groups (<10, 10-15, and >15 years). Medians with 95% confidence intervals of bias, precision, and accuracies within 30% of the iGFRs, for all three formulas, were compared using the Wilcoxon signed-rank test. Results: For the entire cohort and for all CKD and age groups, medians of bias for the CKD-EPI formula were significantly higher (p < 0.001) and precision was significantly lower than the solely SCreat and the combined SCreat and CysC Schwartz formulas. We also found that using the CKD-EPI formula, bias decreased and accuracy increased while the child age group increased, with a better formula performance above 15 years of age. However, the CKD-EPI formula accuracy is 58% compared to 93 and 92% for the SCreat and combined Schwartz formulas in this adolescent group. Conclusions: The performance of the combined CKD-EPI formula improves in adolescence compared with younger ages. Nevertheless, the CKD-EPI formula performs more poorly than the SCreat and the combined Schwartz formula in pediatric population.

show abstract

“…Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group defined CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health (28).…”

Section: Definition Of Chronic Kidney Disease In Cirrhotic Patientsmentioning

confidence: 99%

Renal dysfunctions in cirrhosis

2016

View full text Add to dashboard Cite

Kidney dysfunction is a common and potentially life-threating event in patients with cirrhosis, and underlying mechanisms for renal dysfunction are quite variable. Acute kidney injury (AKI) is relatively frequent encountered in approximately 20% of hospitalized patients with cirrhosis. Nevertheless, chronic kidney disease (CKD) occurs in almost 1% of all patients with cirrhosis. In this review various renal problems encountered in cirrhotic patients are discussed and strategies to prevent renal dysfunction are suggested.

show abstract

Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’

Cited by 965 publications

References 6 publications

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Combined Serum Creatinine and Cystatin C Schwartz Formula Predicts Kidney Function Better than the Combined CKD-EPI Formula in Children

Renal dysfunctions in cirrhosis

Contact Info

Product

Resources

About